Hangzhou Tangji Medical Technology Co., Ltd. has filed its IPO prospectus with the Hong Kong Stock Exchange, targeting a main board listing to capitalize on its position as China’s pioneer in endoscopic obesity treatment. The company’s flagship Gastric Bypass Stent System (GBS), first approved by NMPA in January 2024 as a Class III innovative medical device, offers a minimally invasive alternative to bariatric surgery for weight loss and metabolic disease management.
Transaction Overview
Element
Detail
Company
Hangzhou Tangji Medical Technology Co., Ltd.
Listing Venue
Hong Kong Stock Exchange (Main Board)
Filing Date
Week of 09 Feb 2026
Founded
2016
Sector
Medical devices – obesity and metabolic disease
Use of Proceeds
Expected to fund commercialization, R&D pipeline, and manufacturing scale-up
Flagship Product: Gastric Bypass Stent System (GBS)
Feature
GBS Specification
Clinical Value
Design Inspiration
Roux-en-Y Gastric Bypass (RYGB) surgery
Mimics metabolic benefits of gold-standard bariatric procedure
Delivery
Endoscopic, minimally invasive
No abdominal incisions; reduced recovery time vs. surgery
Regulatory Status
Class III innovative medical device (NMPA, Jan 2024)
First device in China approved for endoscopic obesity treatment
Mechanism
Stent-based gastric bypass simulation
Restricts food intake and alters nutrient absorption pathways
Target Population
Obese patients (BMI ≥28) with metabolic comorbidities
Bridge between lifestyle intervention and invasive surgery
Market Context & Strategic Positioning
Factor
Market Implication
China Obesity Epidemic
>50% of adults overweight/obese; 120 million with BMI ≥28; bariatric surgery penetration <1% due to invasiveness and cost
Endoscopic Bariatrics Gap
No approved devices prior to GBS; massive unmet need between drugs (GLP-1 shortages) and surgery
GLP-1 Synergy/Competition
GBS offers procedural alternative to semaglutide/tirzepatide for patients seeking durable non-pharmacological solution
Innovative Device Premium
Class III designation enables NRDL negotiation priority and hospital procurement preference under China’s medical device localization policy
Pipeline & Comprehensive Cycle Management
Strategic Focus
Execution Plan
GBS Commercialization
Scale manufacturing; train endoscopists in tier-1/2 hospitals; establish reimbursement pathway
Product Line Expansion
Adjunctive devices for stent management, metabolic monitoring, and patient compliance
Digital Health Integration
Comprehensive cycle management platform combining device data with lifestyle coaching
Global Expansion
CE Mark and FDA regulatory pathway initiation post-HK listing
Competitive Landscape
Competitor
Product
Status
Tangji Differentiation
ValenTx
Endoscopic bypass sleeve (US/EU)
CE Mark; not in China
GBS first-mover China advantage; tailored to Asian anatomy
EndoBarrier
Duodenal-jejunal bypass liner
Limited commercial traction
GBS mimics RYGB more closely; superior metabolic outcomes
Forward‑Looking Statements This brief contains forward‑looking statements regarding Tangji Medtech’s Hong Kong IPO pricing and timing, GBS commercial adoption in Chinese hospitals, and endoscopic bariatric device market expansion. Actual results may differ due to HKEX listing approval delays, reimbursement negotiation outcomes with NMPA/NRDL, and competitive entry from global device manufacturers.-Fineline Info & Tech
By Fineline Cube 